Hagens Berman Alerts Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
January 19 2016 - 8:00AM
Hagens Berman Sobol Shapiro LLP, a national investor-rights law
firm, alerts Esperion Therapeutics, Inc. (NASDAQGM:ESPR) investors
there is a March 14, 2016 lead plaintiff deadline in the securities
fraud class action lawsuit filed against the Company related to the
delayed approval of Esperion’s leading cholesterol drug.
If you suffered losses because of your purchases of Esperion
securities between August 18, 2015 and September 28, 2015, contact
Hagens Berman Partner Reed Kathrein, who is leading the firm’s
investigation by calling 510-725-3000, emailing ESPR@hbsslaw.com or
visiting https://www.hbsslaw.com/cases/ESPR. The lawsuit was
filed in the U.S. District Court for the Eastern District of
Michigan and investors have until March 14, 2016 to move the court
to participate as a lead plaintiff.
Esperion Therapeutics is a pharmaceutical company focused on
developing drugs to lower LDL cholesterol. According to the
complaint, by early August 2015, Esperion completed Phase 2b
clinical trials for its leading product candidate, ETC-1002, and
was meeting with the FDA to discuss moving forward with the Phase 3
segment of the approval process. On August 17, 2015, Esperion
relayed to investors material events from its meeting with the FDA,
and stated that the FDA informed the company that it would not have
to complete rigorous cardiovascular trials in order to gain
approval of ETC-1002. Esperion further stated that the company was
pleased with the outcome of the meeting and that the FDA gave it a
“clear regulatory path forward for development and approval of
ETC-1002.”
Then on September 28, 2015, Esperion reversed course about the
FDA meeting, stating that the FDA had actually encouraged the
company to initiate a cardiovascular trial and it may be necessary
to complete these trials before ETC-1002 would be approved. On this
news, Esperion stock fell by $16.76 per share, or nearly 50%, to
close at $18.33 per share on September 29, 2015. The complaint
alleges Esperion misled investors when they made statements about
the FDA meeting that they reversed in later announcements.
If you are an investor who held Esperion securities between
August 18, 2015 and September 28, 2015 and would like to learn more
about this lawsuit, your ability to participate as a lead
plaintiff, or our investigation, please contact us for your no-cost
evaluation.
Whistleblowers: Persons with non-public
information regarding Esperion should consider their options to
help in the investigation or take advantage of the SEC
Whistleblower program. Under the new SEC Whistleblower program,
whistleblowers who provide original information may receive rewards
totaling up to 30 percent of any successful recovery made by the
SEC. For more information, call Reed Kathrein at (510) 725-3000 or
email ESPR@hbsslaw.com.
About Hagens Berman Hagens Berman is headquartered in Seattle,
Washington with offices in 10 cities. The Firm represents
investors, whistleblowers, workers and consumers in complex
litigation. More about the Firm and its successes can be found at
www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit
the blog. For the latest news visit our newsroom or follow us on
Twitter at @classactionlaw.
Contact:
Reed Kathrein
510-725-3000
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024